This targeted inhibition of DNMT1-mediated Foxp3 hypermethylation represents a core mechanism through which JPZS promotes Treg/Th17 rebalancing and ameliorates SLE pathology in this model. The gene discussed is FOXP3; the disease is systemic lupus erythematosus.